

## Special Issue

# Population Immunity and Persistence to SARS-CoV-2 Induced by Infection and Vaccination, Protection Against New Infections and Implication for Further Vaccination: 2nd Edition

### Message from the Guest Editors

After the World Health Organization declared the end to COVID-19's emergency phase, SARS-CoV-2 continues to evolve. Having a knowledge of population immunity landscape and dynamics, understanding its protection against infections of variants and severity after infections, is critical for policy-making on actions that countries should take in the future. However, global, regional and national population immunity and their dynamic changes remain unknown, since it is complex and varied due to disparity of infections history and vaccination coverage across the world. The Special Issue aims to collect the latest research results on the sero-epidemiological characteristics of SARS-CoV-2 infections and vaccination. We are pleased to invite the submission of original research articles and reviews investigating the infection incidence and its severity, population immunity landscape and the kinetics of antibodies following prior infections (with any variant), vaccination (particularly post-licensure) or both (hybrid immunity), protection (and cross-protection) against new variants infections, and providing new ideas for the COVID-19 vaccination strategy in the future, etc.

---

### Guest Editors

Dr. Juan Yang

School of Public Health, Fudan University, Shanghai, China

Dr. Wei Wang

School of Public Health, Fudan University, Shanghai, China

---

### Deadline for manuscript submissions

closed (31 May 2026)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/224616](https://mdpi.com/si/224616)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).